Signaling-mediated control of ubiquitin ligases in endocytosis
© Polo; licensee BioMed Central Ltd. 2012
Received: 30 November 2011
Accepted: 15 March 2012
Published: 15 March 2012
Skip to main content
© Polo; licensee BioMed Central Ltd. 2012
Received: 30 November 2011
Accepted: 15 March 2012
Published: 15 March 2012
Ubiquitin-dependent regulation of endocytosis plays an important part in the control of signal transduction, and a critical issue in the understanding of signal transduction therefore relates to regulation of ubiquitination in the endocytic pathway. We discuss here what is known of the mechanisms by which signaling controls the activity of the ubiquitin ligases that specifically recognize the targets of ubiquitination on the endocytic pathway, and suggest alternative mechanisms that deserve experimental investigation.
Ubiquitination modifies proteins in a variety of ways, the significance of which we only partially comprehend. Ubiquitin can be attached: as an individual moiety to a single or multiple lysine residues of substrate (mono- or multiple monoubiquitination); as chains of ubiquitin moieties that are interlinked through any one of the seven lysine residues of ubiquitin (for example K48- or K63-linked chains); or as branched chains, to name but a few . The cell interprets each of these modifications as a distinct signal. The first described role of ubiquitination as mediating protein degradation through targeting to the proteasome has now been complemented with numerous other functions . For example, the signal encoded by K63-linked chains can mediate functions as diverse as receptor endocytosis [3, 4], activation of protein kinases in the NF-κB pathway and the initiation of error-free DNA repair .
Signal transduction from transmembrane cell surface receptors to nuclear transcription factors is regulated at multiple levels by protein ubiquitination. The covalent attachment of one, or often more, ubiquitin moieties has emerged as the principal mechanism for termination of signaling, by targeting the receptor for endocytosis and, ultimately, degradation in the lysosome . This device controls a vast array of mammalian signaling receptors, such as receptor tyrosine kinases, G-protein coupled receptors (GPCRs), growth hormone receptors, the major histocompatibility complex I, NOTCH, various channels and transporters, and cytokine and interferon receptors . Receptors that are internalized after activation are directed first into the endosomes of the endocytic pathway, and then into multivesicular bodies (MVBs), which undergo a process of maturation that ends with fusion with the lysosome and delivery of the contents for degradation. Ubiquitination of the receptor provides the crucial signal for entering this pathway [3, 5–7].
The inducibility of the system illustrates the dynamic nature of ubiquitin-based endocytic regulation. Indeed, over the past 15 years, studies from different laboratories have revealed a critical role for ubiquitination in receptor down-regulation, a process that is essential for the spatial and temporal resolution of receptor signaling .
The central component of this regulatory pathway is the E3 ligase that attaches the ubiquitin molecules to the receptor, or to the ubiquitin-binding endocytic adaptors (Figure 1). A hierarchical set of three types of enzyme is required for substrate ubiquitination: ubiquitin-activating (E1), ubiquitin-conjugating (E2) and ubiquitin-protein ligase (E3) enzymes. In mammals two E1-activating enzyme transfer ubiquitin to roughly three dozen E2s, which function together with several hundred different E3 ubiquitin ligases to ubiquitinate thousands of substrates. In the endocytic pathway distinct E3 enzymes generally catalyze the ubiquitination of the cell-surface receptors and the endosomal sorting proteins . Therefore the endocytic sorting of a given target generally involves more than one E3 ubiquitin protein ligase.
Here we focus on how signaling controls the activity of the E3 ligases that ubiquitinate receptors and endocytic adaptors. Although E3 ligases have largely been considered to be constitutively active and regulated only at the level of target binding, it has recently become evident that they are subject to regulation by either E3 or substrate phosphorylation, or by exploitation of adaptor proteins that facilitate E3 activity. We discuss here the various ways of regulating E3 ligases in the context of endocytosis.
Another class of E3 ligases, the HECT NEDD4 family , whose regulation has been extensively studied, also regulates endocytosis and sorting of numerous signaling receptors [3, 5–7]. These enzymes present a conserved modular organization with an amino-terminal C2 domain that is crucial for membrane localization, between two and four WW domains capable of recognizing substrates and adaptor proteins through PY motifs, and a carboxy-terminal catalytic HECT domain. In contrast to RING-based ligases in which the RING is an allosteric activator of the E2, HECT-containing E3s have intrinsic catalytic activity and directly ubiquitinate their targets. In humans, there are nine members of this family: NEDD4 (also known as NEDD4-1), NEDD4L (also known as NEDD4-2), ITCH (also known as AIP4), WWP1, WWP2, SMURF1, SMURF2, NEDL1 (also known as HECW1) and NEDL2 (also known as HECW2). Rsp5 is the unique, essential member of the NEDD4 family in Saccharomyces cerevisiae. In normal conditions most of them appear to be in an inactive state because of an intramolecular inhibitory interaction between the carboxy-terminal HECT and the amino-terminal C2 domain (in the case of SMURF2, NEDD4 and WWP2 ) or the WW domains (in the case of ITCH ). Activation of this class of enzyme can occur in various ways that are briefly described below.
In the case of SMURF2, autoinhibition of the HECT domain by the C2 domain helps in maintaining the steady-state levels of this E3 ligase and can be relieved by adaptor-mediated substrate targeting . SMURF1 and SMURF2 bind to TGF-β family receptors through the inhibitory Smad proteins, SMAD6 and SMAD7, to induce their ubiquitin-dependent degradation. Wiesner et al.  demonstrated that intramolecular interactions between the C2 and HECT inhibit SMURF2 catalytic activity interfering with ubiquitin thioester formation. This in cis autoinhibition can be relieved by binding of the amino-terminal domain (NTD) of the adaptor protein SMAD7 to the E3 HECT domain (Figure 3b). The SMAD7 NTD further enhances the catalytic activity of the SMURF2 ligase by recruiting the E2 UbcH7 to the HECT domain . By releasing C2-mediated autoinhibition, stimulating E2 binding, and recruiting SMURF targets, SMAD7 functions at multiple levels to control E3 activity and ensure specificity in SMURF-catalyzed ubiquitination.
Recently, a role for a UBD present on the N-lobe of the HECT domain of NEDD4 and Rsp5 has been identified [28, 29]. The ability of the HECT domain to bind non-covalently to the distal ubiquitin at the growing end of the polyubiquitin chain on the substrate allows enzyme processivity . It is tempting to attribute an inhibitory role of the C2 binding for this critical feature of these enzymes. Accessibility of the UBD may be restored in response to upstream signaling events capable of inducing phosphorylation and/or ubiquitination of critical sites in the C2 or in the HECT domain, leading to full ligase activation. While this hypothesis needs to be experimentally verified, we notice that ubiquitination of NEDD4 is a critical event for the coupled monoubiquitination of EPS15 ( and below).
Finally, specific binding proteins can regulate the process of ubiquitination by acting as adaptors to recruit E3 proteins to receptors that lack a direct binding motif for the ligase (reviewed in ). The best evidence for this mechanism so far comes from membrane transport directed by the yeast HECT E3 ligase Rsp5, which is the unique homolog of the mammalian NEDD4 family proteins. While in humans there are nine members of the NEDD4 family, yeast Rsp5 is sufficient on its own to control most membrane traffic ubiquitination events at the plasma membrane and at other biomembranes . Cooperation with adaptors such as Bul1/Bul2, Bsd2/Tre1/Tre2, or Ear1/Ssh4 enables Rsp5 to cope with this large number of substrates , and the discovery of the yeast family of ARR-related proteins (ARTs), which direct Rsp5 activity to various plasma membrane receptors [36–38], shows that the adaptor mechanism is even more extensive than previously thought (Figure 4b). Does receptor signaling regulate these HECT adaptor proteins? Two recent papers provide evidence that it does [39, 40]. MacGurn et al.  demonstrated that signaling from TORC1, which is a central regulator of cell growth in response to amino acid availability, regulates Rsp5 targeting and endocytosis of nutrient transporters at the plasma membrane. The effector mechanism that regulates endocytosis involves a TORC1-Npr1 negative kinase signaling cascade that tunes the phosphoinhibition of the ubiquitin ligase adaptor Art1 . Leon and colleagues  identified the α-arrestin Rod1/Art4 as a direct target of the glucose signaling pathway. Glucose promotes Rod1/Art4 dephosphorylation and its subsequent release from a phospho-dependent interaction with 14-3-3 proteins. This allows Rsp5-mediated Rod1 ubiquitination, a prerequisite for transporter endocytosis . It is conceivable that other signaling pathways may similarly regulate the activity of other ART family proteins.
Does this mechanism also operate in mammals? And if yes, how? These important gaps in our understanding need to be filled. Of note, arrestin domain containing protein 3 (ARRDC3) was recently shown to interact with NEDD4 and to be an essential adaptor for β2-adrenergic receptor (β2AR) ubiquitination .
ARR is not the sole example of an endocytic adaptor subjected to ubiquitin modification. Several components of the downstream endocytic machinery are monoubiquitinated upon RTK activation [10, 11, 44, 45]. In most cases, these adaptors are ubiquitin receptors that are ubiquitinated by the E3 ligase NEDD4. The presence of a UBD is required for monoubiquitination of the UBD-harboring adaptor, in a process termed coupled monoubiquitination whose molecular workings have been elucidated using the endocytic proteins EPS15 and EPSIN-1 as models [30, 46] (Figure 5b). By contrast, the mechanism by which NEDD4 recruitment is induced by the activated EGFR remains to be clarified.
What is the role of adaptor ubiquitination? Monoubiquitination might permit the formation of several tiers of ubiquitination-dependent interactions in the endosome, by allowing binding of ubiquitinated cargo (through UBDs) and recruiting another layer of ubiquitin receptors through the monoubiquitin signal. The result would be signal amplification and progression of ubiquitinated cargoes along the endocytic pathway.
Monoubiquitination of ubiquitin receptors may also result in an intra-molecular interaction between their UBDs and monoubiquitinated residues, with resulting dissociation from the ubiquitinated cargo [47, 48]. These two possibilities are not mutually exclusive and both mechanisms may be involved in the regulation of endocytic processes, possibly by acting at distinct steps and/or regulating different endocytic adaptors.
It is important to realize that the power of ubiquitin stems from its capacity to act as a protein-protein interaction module that targets substrates to a plethora of downstream effectors. In order to realize this network, complex molecular machines generate and recognize signal diversity based on ubiquitin-binding modules. The network is fine-tuned by ubiquitinating (E3 ligases) and deubiquitinating enzymes (DUBs) that balance the absolute levels of protein ubiquitination, as well as the abundance and localization of adaptors that contain docking sites for specific ubiquitinated proteins (UBDs) .
One such network pivots around EGFR. EGF stimulation promotes ubiquitination of EGFR and of EGFR endocytic adapters, providing a striking example of concerted regulation of signaling, ultimately regulating the route of EGFR internalization [50, 51]. Our own approach to understanding the complex interplay between EGFR-induced signaling circuitries has been the recent elucidation of the EGF-induced 'ubiproteome' . This work has uncovered an extensive ubiquitin-based signaling network that impinges on a wide array of signaling circuitries and various aspects of cellular physiology including DNA repair, nuclear transport, mRNA processing, metabolic pathways, and ribosome biogenesis. Interestingly, many ubiquitin machinery enzymes were detected in the EGF-induced ubiproteome. Regardless of the initial triggering mechanism (which necessarily involves the kinase activity of the EGFR), the ubiquitin signal seems to be rapidly transmitted to, and amplified through, the ubiquitin machinery. Just as in the phosphorylation cascade, in which critical enzymes such as kinases and phosphatases are often activated by phosphorylation, ubiquitinating enzymes appear to be regulated by ubiquitination. Moreover, a comparison of the EGF-induced ubi- and pY-proteomes revealed a significant overlap and identified many highly connected 'hub' proteins that are both phosphorylated and ubiquitinated . These data suggest that two complementary and interlinked enzymatic cascades drive the flow of information from receptors to downstream signaling molecules: kinases/phosphatases and E3 ligases/DUBs. In essence, these two post-translational-modification-based networks can be conceptualized as two overlapping, diffusely interconnected, matrices through which external signals are transduced and interpreted by the cell. To understand how this is achieved, a multidisciplinary approach is required. No single 'omics' analysis can fully unravel the complexities of the system. Complete understanding will be achieved only by integrating information from high-resolution molecular investigations, 'omics' approaches and 'top-down' systems-based modeling.
Research in the Polo laboratory is supported by grants from the Associazione Italiana per la Ricerca sul Cancro, the Italian University Research Program for the Development of Research of National Interest and of Health (PRIN), the Association of International Cancer Research, the CARIPLO Foundation, and the EMBO Young Investigator Program.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.